Conatus Pharmaceuticals Stock Price - CNAT

0.0142 (3.05%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Conatus Pharmaceuticals Inc CNAT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0307 7.06% 0.4657 0.427 0.476 0.4311 0.435 00:00:01
Bid Price Ask Price Spread Spread % News
0.45 0.48 0.03 6.25% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,487 914,079 $ 0.4522978 $ 413,436 1,100,339 0.25 - 3.08
Last Trade Time Type Quantity Stock Price Currency
18:01:39 formt 100 $ 0.4799 USD

Conatus Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 15.45M 33.17M $ -18.01M -0.59 -1.13 32.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Conatus Pharmaceuticals News

Loading Messages....

Latest CNAT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CNAT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.44320.4760.42180.4382333304,6090.02255.08%
1 Month0.42960.57990.350.44772191,132,4570.03618.4%
3 Months0.35250.57990.340.4208874879,4350.113232.11%
6 Months0.3250.57990.290.3892143732,2030.140743.29%
1 Year1.873.080.250.7242357868,657-1.40-75.1%
3 Years5.119.400.253.14701,645-4.64-90.89%
5 Years6.399.400.253.59653,586-5.92-92.71%

Conatus Pharmaceuticals Description

Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

Your Recent History
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.